Pathogenic Germline Mutational Landscape in Patients With Renal Cell Carcinoma and Associated Clinicopathologic Features
JCO Precision Oncology · 2023-09 · (7)
DOI: 10.1200/po.23.00168 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-09. Verfasst von Charles B Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE A subset of renal cell carcinoma (RCC) cases occur because of a hereditary predisposition. However, the prevalence and profiling of germline alterations in RCC have not been fully characterized. Additionally, clinicopathologic factors associated with pathogenic or likely pathogenic (P/LP) germline variants in patients with RCC remain poorly understood. METHODS A retrospective analysis of patients with RCC who underwent genetic evaluation was performed. The frequency of P/LP germline variants and genes was evaluated in this cohort. The association between genetic testing outcomes and clinicopathologic features was also assessed. RESULTS A total of 321 patients with RCC who had germline testing were identified. Within this cohort, 42 patients (13.1%) had P/LP variants. Genes with the most frequent germline mutations were FLCN (n = 10, 3.1%), SDHB (n = 4, 1.2%), VHL (n = 4, 1.2%), MLH1 (n = 3, 0.9%), and CHEK2 (n = 4, 1.2%). Among patients with P/LP variants, 19 (45.2%) had a potentially targetable mutation. The presence of bilateral or multifocal tumors was associated with P/LP variants ( P = .0012 and P = .0098, respectively). Patients who had targeted gene testing had higher rates of P/LP variants compared with multigene panel testing ( P = .015). Age and family history of cancers (RCC and non-RCC) did not have any statistically significant association with germline testing outcomes. CONCLUSION Among patients with RCC, unselected for a known familial predisposition, 13.4% had P/LP variants. Almost half of patients with P/LP variants had a potentially targetable mutation. Targeted gene panel testing is a feasible option for patients, particularly if syndromic features are present. Age and family history were not associated with P/LP variants. Future studies are needed to optimize current genetic evaluation criteria to expand the detection of patients with RCC who may have germline mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI.
- Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
ORCID-Profile: Charles B Nguyen, Ulka N Vaishampayan
Förderung
- NCI NIH HHS
Zitieren
APA
Nguyen, C. B., Knaus, C., Li, J., Accardo, M. L., Koeppe, E., Vaishampayan, U. N., Alva, A. S., & Else, T. (2023). Pathogenic Germline Mutational Landscape in Patients With Renal Cell Carcinoma and Associated Clinicopathologic Features. JCO Precision Oncology. https://doi.org/10.1200/po.23.00168
Vancouver
Nguyen CB, Knaus C, Li J, Accardo ML, Koeppe E, Vaishampayan UN, et al. Pathogenic Germline Mutational Landscape in Patients With Renal Cell Carcinoma and Associated Clinicopathologic Features. JCO Precision Oncology. 2023. doi:10.1200/po.23.00168
BibTeX
@article{Nguyen2023,
author = {Nguyen, Charles B and Knaus, Claire and Li, Jinju and Accardo, Marie-Louise and Koeppe, Erika and Vaishampayan, Ulka N and Alva, Ajjai S and Else, Tobias},
title = {Pathogenic Germline Mutational Landscape in Patients With Renal Cell Carcinoma and Associated Clinicopathologic Features},
journal = {JCO Precision Oncology},
year = {2023},
number = {7},
doi = {10.1200/po.23.00168}
}
EUVIMED